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Objectives This study sought to study the second-generation everolimus-eluting stent (EES) as
compared with ﬁrst-generation sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) in diabetes
mellitus (DM) patients.
Background There are limited data available comparing clinical outcomes in this setting with EES
and SES, whereas studies comparing EES with PES are not powered for low-frequency endpoints.
Methods All DM patients treated with EES, PES, or SES from January 18, 2007, to July 29, 2011,
from the SCAAR (Swedish Coronary Angiography and Angioplasty Registery) were included. The EES
was compared with SES or PES for the primary composite endpoint of clinically driven detected re-
stenosis, deﬁnite stent thrombosis (ST), and all-cause mortality.
Results In 4,751 percutaneous coronary intervention-treated DM patients, 8,134 stents were im-
planted (EES  3,928, PES  2,836, SES  1,370). The EES was associated with signiﬁcantly lower
event rates compared with SES (SES vs. EES hazard ratio [HR]: 1.99; 95% conﬁdence interval (CI): 1.19
to 3.08). The same was observed when compared with PES (PES vs. EES HR: 1.33; 95% CI: 0.93 to
1.91) but did not reach statistical signiﬁcance. These results were mainly driven by lower incidence
of ST (SES vs. EES HR: 2.87; 95% CI: 1.08 to 7.61; PES vs. EES HR: 1.74, 95% CI: 0.82 to 3.71) and mor-
tality (SES vs. EES HR: 2.02; 95% CI: 1.03 to 3.98; PES vs. EES HR: 1.69; 95% CI: 1.06 to 2.72). No sig-
niﬁcant differences in restenosis rates were observed between EES and SES or PES (SES vs. EES HR:
1.26; 95% CI: 0.77 to 2.08; PES vs. EES HR: 1.05; 95% CI: 0.71 to 1.55).
Conclusions In all-comer DM patients the use of EES was associated with improved outcomes com-
pared with SES and PES mainly driven by lower rates of ST and mortality. These results suggest bet-
ter safety rather than efﬁcacy with EES when compared with SES or PES. (J Am Coll Cardiol Intv
2012;5:1141–9) © 2012 by the American College of DM
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1142The introduction of the first-generation sirolimus-eluting
(SES) and paclitaxel-eluting stents (PES) has led to mark-
edly reduced restenosis rates and reduced need for target
lesion revascularization, compared with bare-metal stents,
in DM patients as well as non-DM patients (1–5). How-
ever, DM remains associated with increased risk of in-stent
restenosis, target lesion revascularization, and target vessel
revascularization in patients undergoing percutaneous cor-
onary interventions (PCI) (6). The second-generation
everolimus-eluting stent (EES) has recently been found to
be superior to the first-generation PES for reduction of
target lesion revascularization, target vessel revasculariza-
tion, and stent thrombosis (ST) in 2 large randomized trials;
however, these significant improvements in safety and
efficacy endpoints were limited to the nondiabetic subgroup
of patients, because no differences in treatment effect be-
tween these 2 stents were observed in DM patients in both
trials (7,8). These findings were
further confirmed by a large
patient-level pooled analysis from
4 randomized clinical trials com-
paring EES with PES (9).
Whether these results hold true in
larger all-comer populations is un-
known. There is a paucity of data
on differences in clinical outcomes
between EES and SES for treat-
ment of DM patients, because the
only data available derive from a
relatively small series of patients
and therefore are not adequately
powered to detect low-frequency
endpoints (10). Different issues
with regard to the impact of metal
alloy, strut thickness, polymer bio-
compatibility, and especially the
effect of eluted active principle in
atients with DM still remain unanswered. Therefore, we
ompared the safety and efficacy of the second-generation
ES with the most-studied first-generation drug-eluting
tent (DES), represented by the SES and PES in diabetic
atients, with the data from the SCAAR registry (Swedish
oronary Angiography and Angioplasty Register) (11).
ethods
Study sample. For the present analysis we studied all PCI-
treated DM patients from the SCAAR database. During
the period from January 18, 2007, to July 27, 2011, 71,639
PCIs with stent implantations were performed in Sweden,
of which 13,830 (19.3%) were in DM patients. A total of
110,610 stents were implanted. Of these, 21,962 (19.8%)
stents were used in DM patients, 87,789 in non-DM
Abbreviations
and Acronyms
CI  confidence interval
CTO  chronic total
occlusion
DES  drug-eluting stent(s)
DM  diabetes mellitus
EES  everolimus-eluting
stent(s)
HR  hazard ratio
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent
SES  sirolimus-eluting
stent(s)
ST  stent thrombosispatients, and 859 in patients without information aboutDM status. Of the 21,962 stents implanted in DM patients,
11,493 were BMS, and 47 were not classified as BMS or
DES. Of the remaining 10,422 DES, 30 were excluded in
the analysis due to missing data. Of these 10,422 DES,
2,836 were PES, 1,370 were SES, and 3,929 were EES,
whereas the remaining 2,258 stents represent Biolimus-
eluting and Zotarolimus-eluting stents (not included in
these analyses).
The SCAAR registry has been previously described
(11,12). Briefly, this registry holds data on consecutive
patients from all 29 centers that perform coronary angiog-
raphy and PCI in Sweden. The registry is sponsored by the
Swedish Health Authorities and is independent of commer-
cial funding. The technology is developed and administered
by the Uppsala Clinical Research Centre. Since 2001, the
SCAAR registry has been web-based, with recording of
data online through a Web-interface in the catheterization
laboratory; data are transferred in an encrypted format to a
central server at the Uppsala Clinical Research Centre. All
patients undergoing a coronary angiography or a PCI
procedure nationwide are included. Since May 2005, all
information with respect to restenosis and ST of previously
treated patients that return in the catheterization laboratory
for subsequent coronary angiography or PCI is entered in
the SCAAR registry as well as the indication of such
procedures. The web-based system provides each center
with immediate and continuous feedback on processes and
quality-of-care measures. Monitoring and verification of
registry data are periodically performed in all hospitals since
2001 by comparing 50 entered variables in 20 randomly
selected interventions/hospital and year with patient hospi-
tal records.
Study design and endpoints. The SCAAR registry includes
follow-up data for every implanted stent device, permitting
device-oriented as well as patient-oriented endpoint analy-
sis. For the current analysis the EES was compared indi-
vidually with PES and SES in DM patients. Diabetes
mellitus was defined either by patient-reported diagnoses on
clinical files at baseline or use of antidiabetic medication
before procedure. The primary endpoint of the study was a
composite safety and efficacy endpoint of all-cause mortal-
ity, ST, and restenosis at 1 year.
The restenosis and ST are performed at device level,
whereas mortality is analyzed at patient level. The same
definition for restenosis, as defined by the SCAAR steering
committee, was used. The SCAAR definition of restenosis
is defined as a stenosis assessed by angiographic visual
estimation (50%) or by fractional flow reserve value of
0.80 in a previously stented segment identified by coro-
nary angiography for any clinical indication in any of the 29
centers in Sweden (11,12). The clinical relevance of rest-
enotic lesions was detected by symptoms, routine noninva-
sive functional testing (exercise test, nuclear scan) and/or
invasive functional evaluation by fractional flow reserve. The
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1143clinically driven detected restenosis, the efficacy endpoint in
this study, differs from the classical target lesion revascular-
ization endpoints used in other large studies. The target
lesion revascularization combines revascularizations per-
formed due to restenosis as well as ST and therefore might
introduce biases, especially for high-risk populations treated
with first-generation DES, where the ST can generate a
consistent percentage of the target lesion revascularization
events.
Stent thrombosis was defined in the SCAAR registry as
an angiographic occlusion or a nonocclusive thrombus in a
previously implanted stent with an acute clinical presenta-
tion (13), a definition that highly resembles the American
College of Radiology definition of definite ST (14).
All-cause mortality data were obtained from the National
Population Death Registry. The merging of the registries
was performed by the Epidemiologic Centre of the Swedish
National Board of Health and Welfare and approved by the
local ethical committee at Uppsala University.
Statistical analysis. The baseline clinical and angiographic
haracteristics were compared by means of the chi-square
est for categorical variables and analysis of variance for the
ontinuous variables. Stent groups were compared with
urvival analyses. The Kaplan-Meier estimator was used to
ompute cumulative hazards and Cox proportional hazards
egression to estimate hazard ratios (HRs). Differences
etween stent groups in baseline characteristics were ad-
usted with propensity score methods. Two different pro-
ensity scores were created, both defined as the conditional
robability of having an EES, 1 in populations of stents
ith only EES or PES, and the other in a population with
nly EES or SES. The following variables were forced into
ogistic regression models: previous myocardial infarction,
oronary artery bypass grafting, or PCI; sex; hypertension;
yperlipidemia; smoking; prior aspirin, clopidogrel, or war-
arin use; anticoagulant use; glycoprotein IIb/IIIa inhibitor
se; number of vessel disease; graft; restenosis; chronic
cclusion; indication for PCI; complete revascularization;
ifurcation lesion; type of lesion; and hospital. These
ropensity scores were entered in Cox proportional hazards
odels together with the type of stent drug and the year of
CI procedure to calculate the adjusted HR for ST and
estenosis. In a similar way 2 additional propensity scores
ere created and used in the outcome analysis of all-cause
ortality, including the following variables: previous myo-
ardial infarction, coronary artery bypass grafting, or PCI;
ex; hypertension; hyperlipidemia; smoking; number of
essel disease; indication for PCI; complete revasculariza-
ion; bifurcation lesion; and hospital. Discrimination, cali-
ration, and distribution of all 4 different propensity scores
ere checked. The C-index value and the p value for the
osmer and Lemeshow test in the EES versus PES
estenosis and ST propensity score were 0.775 and 0.81,espectively; for the EES versus SES Restenosis and ST gropensity score: 0.897 and 0.450, respectively; for Everoli-
us versus Paclitaxel Mortality propensity score: 0.791 and
.335, respectively; and for Everolimus versus Sirolimus
ortality propensity score: 0.897 and 0.917, respectively.
The restenosis and definite ST endpoint were evaluated
n medically treated DM patients as stratified for insulin
reatment. Statistical interaction between insulin treatment
nd stent type was examined by introducing these variables
s interaction terms in the Cox proportional hazard models.
All statistical analyses were performed with SPSS (ver-
ion 19, SPSS, Chicago, Illinois).
esults
A total of 4,751 DM patients were treated with PCI and
were included in the present study. These patients received
8,134 DES: 3,928 EES (average 2.23 1.25 stent/patient),
2,836 PES (average 2.03  1.11 stent/patient), 1,370 SES
(average 2.34  1.34 stent/patient). Baseline characteristics
of the groups are shown in Table 1. Although baseline
clinical and angiographic results were in general well-
balanced, some significant differences were detected.
Clinical outcomes. Clinical outcome data are presented in
able 2.
The EES was associated with significantly lower rates of
dverse events compared with SES (SES vs. EES: HR:
.99; 95% confidence interval [CI]: 1.19 to 3.08). A similar
rend was observed also when compared with PES (HR:
.33; 95% CI: 0.93 to 1.91) (Fig. 1, Table 2). No significant
ifferences were observed in the insulin-dependent DM, as
n the noninsulin-dependent DM, but a trend toward better
utcomes was observed in these subgroups when comparing
ith SES as well as PES.
The EES was associated with significantly lower rates of
ll-cause mortality, compared with SES or PES after
djustment for propensity scores (SES vs. EES: HR: 2.02,
5% CI: 1.03 to 3.98; PES vs. EES: HR: 1.69; 95% CI:
.06 to 2.72) (Fig. 2). A trend toward lower mortality rates
ith EES was maintained irrespective of insulin treatment
ut reached significance only for the EES and SES com-
arison in the insulin-treated group, after stratifying for
nsulin treatment (Table 2).
No differences were seen in restenosis rates when com-
aring EES with SES or PES in all DM patients as well as
fter stratifying for insulin treatment (Fig. 3). A trend
oward better outcomes with EES was observed when
ompared with SES in noninsulin-dependent DM patients
SES vs. EES: HR: 1.76, 95% CI: 0.82 to 3.77, p  0.14),
hereas no differences were observed in insulin-treated DM
atients (SES vs. EES: HR: 0.95, 95% CI: 0.48 to 1.88,
 0.88), p for interaction  0.001. In the EES versus
ES comparison, no differences were observed between
roups; however, a small trend for better outcomes with
o
i
9
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1144EES was observed in the insulin-treated DM patient group
(PES vs. EES: HR: 1.21, 95% CI: 0.74 to 1.98, p  0.44),
whereas the opposite trend was observed in noninsulin-
treated DM patient group (PES vs. EES: HR: 0.81, 95%
CI: 0.41 to 1.59, p  0.54), p for interaction 0.001.
Rates of early definite ST were significantly higher for
both PES and SES as compared with EES (PES vs. EES:
HR: 3.78, 95% CI: 1.31 to 10.39; SES vs. EES: HR: 4.45,
95% CI: 1.24 to 15.91) (Fig. 4). At 1 year EES was
associated with numerically lower risk of definite ST com-
pared with PES and SES but reached statistical significance
only when compared with SES (Table 2). A trend toward
better outcomes with EES as compared with PES was
observed in the insulin-dependent DM subgroup (PES vs.
EES: HR: 2.37, 95% CI: 0.97 to 5.81, p  0.06), whereas
the opposite was observed in the noninsulin-dependent DM
patients (PES vs. EES: HR: 0.69, 95% CI: 0.13 to 3.67,
p  0.67), p for interaction 0.001. At 1 year, better
utcomes were observed with EES as compared with SES
n both insulin-dependent DM (SES vs. EES: HR: 2.67,
5% CI: 0.76 to 9.44, p  0.13) and noninsulin-dependent
DM subgroups (SES vs. EES: HR: 3.41, 95% CI: 0.70 to
16.57, p  0.13), p for interaction  0.31.
Discussion
The major findings of the present analysis, the largest study
to date comparing the outcomes of first- and second-
generation DES in DM patients, are: 1) in all-comer DM
patients, use of EES was associated with lower rates of
composite endpoint of restenosis, definite ST, and all-cause
mortality compared with first-generation stents—with sig-
nificant lower rates when compared with SES, and an
important trend also when compared with PES; 2) treat-
ment with EES was associated with a significantly lower
all-cause mortality when compared with SES and PES;
3) EES was associated with lower rates of 1-year definite ST
when compared with SES and a trend for lower ST when
compared with PES; 4) no significant differences in reste-
nosis rates were observed when comparing EES with PES
and SES; and 5) there is a significant interaction for
restenosis outcomes in EES and PES as well as EES and
SES when stratified for noninsulin-treated DM versus
insulin-treated DM patients.
Because DM is becoming the leading cause of cardiovas-
cular mortality in the western world, and taking into
account the epidemic increase of this condition in countries
with fast-developing economies in Asia and South America,
the findings of this study—the first in the row to show
improved clinical outcomes with newer-generation drug-
eluting stent devices when compared with their predeces-
sors—in this high-risk category of patients gain particularTable 1. Baseline Clinical and Angiographic Characteristics
Everolimus Paclitaxel Sirolimus
p
Value
Number of stents (n) 3,928 2,836 1,370
Patient background
Age, yrs 66.7 10.1 67.4 9.865 65.9 9.8 0.001
Female 29.8 30.3 32.0 0.31
Never smoked 36.0 41.5 39.0 0.001
Hypertension-treated 82.3 79.5 77.7 0.001
Hyperlipidemia 77.9 76.9 78.8 0.04
Previous MI 46.1 46.4 44.2 0.50
Previous PCI 41.3 44.9 46.4 0.001
Previous CABG 17.8 18.5 18.2 0.74
Diabetes 100 100 100 0.001
Insulin treatment 47.2 52.3 49.5
No insulin treatment 52.4 47.7 50.2
GP IIb/IIa 9.5 11.9 7.9 0.001
Indication for index procedure 0.001
Stable angina 33.9 35.4 35.8
Unstable angina 53.8 50.6 54.7
STEMI 10.0 11.5 8.1
Other 2.3 2.6 1.3
Treated vessel and lesion type 0.001
LM 3.3 4.1 2.8
LAD 42.8 39.9 42.6
LCX 22.9 24.4 24.2
RCA 26.2 26.3 25.2
Vein graft 4.8 5.3 5.3
1-VD 28.3 28.6 34.3 0.001
2-VD 33.7 32.9 33.4
3-VD 28.2 26.6 25.5
Left main 7.6 9.4 4.4
Type A-B1 lesion 40.9 38.0 33.5 0.001
Type B2-C lesion 59.1 62.0 66.5
De novo 89.8 86.6 80.7 0.001
In-stent restenosis 10.2 13.4 19.3 0.001
CTO 4.9 4.3 6.1 0.08
Stent length (mm) 19.4 7.4 19.4 6.9 18.6 7.2 0.001
Stent diameter (mm) 2.91 0.47 2.87 0.42 2.98 0.54 0.001
Mean number of stents 2.23 1.25 2.03 1.11 2.34 1.34 0.001
Anticoagulant use
Heparin 74.1 84.2 59.0 0.001
LMWH 7.4 3.6 9.3 0.001
Bivalirudin 17.6 11.4 30.9 0.001
Antiplatelet before PCI
Aspirin 96.2 96.4 95.8 0.74
Clopidogrel 88.2 85.5 85.7 0.002
Warfarin 1.2 1.8 1.2 0.03
Values are n, mean SD, or %.
CABG coronary artery bypass graft; CTO chronic total occlusion; GP IIbIIIa glycoprotein
IIbIIIa inhibitor; LAD  left anterior descending; LCX  left circumflex artery; LM  left main;
LMWH lowmolecular weight heparin; PCI percutaneous coronary intervention; RCA right
coronary artery; STEMI  first-generation ST-segment elevation myocardial infarction; VD importance.
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1145Although the performance of EES and PES in DM
patients has been extensively studied in subgroup analysis
from large randomized trials as well as patient-level pooled
databases, evidence from dedicated randomized trials is still
lacking, and there is a paucity of data comparing EES with
SES in DM patients (8,9,15,16). However, all available
studies comparing EES with SES or PES have been
inadequately powered to provide answers on endpoints, such
as all-cause mortality and ST, as well as provide insights on
treatment effect differences on DM patients when further
stratified according to insulin treatment. Because dedicated
randomized and adequately powered trials to study such
low-frequency events might represent significant organiza-
tional or financial challenges, data from large and well-
organized national databases can be used to provide insights
that can further guide our daily clinical practice and future
research, as is the case here.
The observed lower rates of primary endpoint with EES
reflects mainly in the lower rates of safety endpoints (ST
and mortality), because no significant differences were
observed in clinically meaningful restenosis rates, the effi-
cacy endpoint of this study. Strikingly, there was a signifi-
cant difference in all-cause mortality between EES and SES
and PES. Such a finding should mainly be attributed to the
magnitude of this analysis, which—with its almost 5,000
patients—represents the largest study that has analyzed the
widely used first-generation SES and PES in comparison
with a second-generation DES in a DM patient population.
As shown in Figures 2 and 4 and Table 2, the observed
lower mortality rates with EES as compared with SES or
PES in DM patients closely parallels the rates of definite
ST. In both analyses the differences arise in the early phase,
Table 2. AH for Restenosis, ST, and All-Cause Mortality
ÀStent Type
Stents
(n)
Restenosis
(n)
AH Ratio
(95% CI)
ST
(n)
AH R
(95%
All diabetics
Everolimus 3,928 113 1.0 27 1
Paclitaxel 2,836 96 1.05 (0.71–1.55) 34 1.74 (0.8
Everolimus 3,928 113 1.0 27 1
Sirolimus 1,370 64 1.26 (0.77–2.08) 18 2.87 (1.0
Insulin-treated
Everolimus 1,855 73 1.0 17 1
Paclitaxel 1,484 68 1.21 (0.74–1.98) 30 2.37 (0.9
Everolimus 1,855 73 1.0 17 1
Sirolimus 678 36 0.95 (0.48–1.88) 12 2.67 (0.7
Noninsulin-treated
Everolimus 2,060 40 1.0 10 1
Paclitaxel 1,352 28 0.81 (0.41–1.59) 4 0.69 (0.1
Everolimus 2,060 40 1.0 10 1
Sirolimus 688 26 1.76 (0.82–3.77) 6 3.41 (0.7
AH adjusted hazard ratio; CI confidence interval; ST stent thrombosis.with curves that remain separated in the late phase; andtherefore the observed lower mortality rates with EES
might be attributed to lower rates in 1-year definite ST.
Indeed, previous studies have shown that ST is strongly
associated with higher rates of mortality or myocardial
infarction (17). Furthermore, these results are in line with
the findings of Sarno et al. (18), in an all-comer (DM
patients included) population from the SCAAR database,
where significant lower rates of definite ST and mortality
were observed with newer-generation stents compared with
first-generation and bare-metal stents.
The second-generation EES has emerged as a very
promising stent with low rates of ST, as concluded from
several large prospective randomized trials with moderate-
risk or all-comer patients, but this is the first time that such
a finding was observed specifically in a large cohort of DM
patients (7,8). Also the pattern of ST reduction with EES
observed in this study strongly resembles findings previously
reported from the aforementioned trials and pooled data-
base analysis (19). Indeed, the difference in ST was already
observed in the early phase and was maintained during the
1-year follow-up. The pathophysiological mechanism(s)
underlying the marked lower rates of ST after EES implan-
tation, although speculative, might relate to specific design
features of this stent. The combination of thin, fracture-
resistant struts; low dose of everolimus; and thrombo-
resistant, non-inflammatory proprieties of the fluorinated
polymer might contribute to the lower rates of early ST with
EES (20,21). By contrast, as observed in preclinical animal
models, the low dose of everolimus elution might prompt a
more rapid and complete stent re-endothelialization (21),
whereas everolimus, mammalian target of rapamycin
inhibition-dependent, selective clearage of macrophages
Patients
(n)
Deaths
(n)
AH Ratio
(95% CI)
Deaths,
Restenosis,
ST (n)
AH Ratio
(95% CI)
1,915 82 1.0 138 1.0
) 1,386 76 1.69 (1.06–2.72) 128 1.33 (0.93–1.91)
1,915 82 1.0 138 1.0
) 717 35 2.02 (1.03–3.98) 74 1.99 (1.19–3.08)
880 49 1.0 85 1.0
) 703 50 1.99 (0.82–4.86) 82 1.50 (0.94–2.40)
880 49 1.0 85 1.0
) 357 24 1.98 (1.07–3.68) 48 1.87 (0.996–3.51)
1,028 33 1.0 53 1.0
) 683 26 1.44 (0.67–3.11) 46 1.19 (0.66–2.13)
1,028 33 1.0 53 1.0
7) 357 11 2.22 (0.75–6.61) 25 2.09 (0.98–4.45)atio
CI)
.0
2–3.71
.0
8–7.61
.0
7–5.81
.0
6–9.44
.0
3–3.67
.0
0–16.5might reduce inflammation (22). The reduction in inflam-
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1146mation, which is even more severe in DM patients than
non-DM patients, and the faster and more complete re-
endothelialization might in turn relate to lower rates of
1-year ST (23). Such advantages offered from EES as
compared with PES in non-DM patients, although in a
lesser magnitude, can be observed also in DM patients, as
shown from the present analysis (24). Interestingly, signif-
icant lower rates of definite ST with EES as compared with
Figure 1. Time to Event Kaplan-Meier Curves of Propensity Score
Adjusted In-Stent Restenosis/Death/ST
(A) Everolimus-eluting stent versus sirolimus-eluting stent; (B) everolimus-
eluting stent versus paclitaxel-eluting stent. CI  conﬁdence interval; HR 
hazard ratio; PCI  percutaneous coronary intervention; ST  stent
thrombosis.PES were also observed in the insulin-treated DM patients,whereas an opposite trend was observed in noninsulin-
treated DM patients. Although such findings can be due to
chance, it is also known that insulin-treated DM represents
the most severe form of this condition, which often has a
longer duration and therefore can be expected to be associ-
ated with a more severe form of coronary disease. This could
be the reason why the rates of ST with PES in the
insulin-treated DM patients (as shown in Table 2) were
higher, as similarly observed in other high-risk populations
(25). However, it cannot be excluded that different treat-
ment effects of EES as compared with PES might be
Figure 2. Time to Event Kaplan-Meier Curves of Propensity Score
Adjusted for All-Cause Mortality
(A) Everolimus-eluting stent versus sirolimus-eluting stent; (B) everolimus-
eluting stent versus paclitaxel-eluting stent. CI  conﬁdence interval; HR 
hazard ratio.
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1147present in DM patients when stratified for insulin treat-
ment; therefore more evidence is needed to clarify this issue.
Another important finding of this study is that, despite its
large size, it could not detect any significant differences in
restenosis rates between EES and PES as well as between
EES and SES. These results corroborate previous findings
from other studies comparing EES with PES or SES in
DM patients (9,10,26). No difference in restenosis rates
between EES and PES or between EES and SES could be
detected, even when the analysis was performed in DM
Figure 3. Time to Event Kaplan-Meier Curves of Propensity Score
Adjusted In-Stent Restenosis
(A) Everolimus-eluting stent versus sirolimus-eluting stent; (B) everolimus-
eluting stent versus paclitaxel-eluting stent. Abbreviations as in Figure 1.patients stratified for insulin treatment; however, a signifi-cant interaction was detected for EES as compared with
PES or SES. Indeed, these findings primarily reflect the
severity and complexity of the coronary disease in DM
patients. These patients are known to have increased oxi-
dative stress and profound endothelial dysfunction, both
factors that are believed to strongly impact intracellular
signal transduction. As a result, the cell growth and migra-
tion inhibition (anti-restenotic effect) exerted from both
paclitaxel or rapamycin analogs is altered in these patients,
resulting in a similarly affected efficacy for both rapamycin-
Figure 4. Time to Event Kaplan-Meier Curves of Propensity Score
Adjusted Definite ST
(A) Everolimus-eluting stent versus sirolimus-eluting stent; (B) everolimus-
eluting stent versus paclitaxel-eluting stent. Abbreviations as in Figure 1.
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1148analogs or PES (27,28). The imbalance in efficacy outcomes
with EES as compared with PES and SES, as indicated
from the respective observed interaction when stratified for
insulin-dependent DM and noninsulin-dependent DM,
might also rely on the impact of the insulin resistance on the
mechanism of action of the active principle eluted from
these stents. Although the mechanism of action of paclitaxel
might be less-influenced from the presence of DM, the
rapamycin (and other rapamycin derivatives) inhibition of
mammalian target of rapamycin might be affected by the
insulin resistance, because it is regulated from glycosylation-
dependent enzymes (29). However, because the intracellular
signaling pathways in these patients are very complex and
not entirely understood, this interpretation should be only
regarded as a hypothesis that needs further investigation. In
the case of EES versus SES comparison in insulin-
dependent DM and noninsulin-dependent DM patients,
although both stents do elute a rapamycin-analog, the
polymer and release kinetics of the SES and EES differ
from each other in that sirolimus is released at a higher dose
and for a longer period than everolimus (30). The SES
specific release kinetics might offer some advantages in
protection from restenosis in DM patients, the magnitude
of which seems to parallel the DM severity. However,
although these release kinetics of SES might in a way
counterbalance the design-related disadvantages—such as
thicker stent struts and polymer layer—and in terms of
efficacy lead to similar outcomes as EES, it might render
this device more vulnerable to ST, as indeed observed.
In light of these findings, the newer, recently introduced,
modern-design rapamycin-analogs or PES with durable
bio-absorbable or polymer-free platforms might theoreti-
cally represent valid alternatives with regard to both safety
and efficacy in percutaneous treatment of DM patients and
therefore need to be studied in large and dedicated random-
ized trials.
Study limitations. This analysis represents a retrospective
tudy; therefore, due to lack of randomization, differences
ight arise on baseline characteristics. However, adjust-
ents for baseline differences were implemented with pro-
ensity score analysis for each individual stent comparison
ncorporating 22 baseline variables. Despite the efforts to
arefully adjust for baseline differences arising from the
onrandomized nature of this study, by means of propensity
core adjustment—described in detail in Methods—several
aseline differences might have not been completely ad-
usted (31). Other unmeasured variables might have influ-
nced the study observations. In this study the analysis of
evice performance was performed on the device level and
herefore can differ slightly from endpoints used in other
rials. Indeed, the clinically driven restenosis detection—the
fficacy endpoint in this study—differs from the classical
arget vessel revascularization/target lesion revascularization
ndpoint; however, in our opinion it offers a more accuratevaluation of device efficacy than the classical endpoints, as
xplained in Methods. Another limitation of this study is
hat the outcomes of myocardial infarction in each cohort
ere not studied in this analysis, because myocardial infarc-
ion events during follow-up are not routinely entered in the
CAAR database. Furthermore, the results on ST are reported
nly as definite ST, because the rates of probable ST could not
e analyzed, due to the previously mentioned limitation.
inally, this analysis incorporates only patients included in
he SCAAR registry; these results represent only the Swed-
sh population and the standard of care. However, Sweden
as adopted the European Society of Cardiology guidelines,
nd therefore we do believe that they can be extrapolated to
he rest of the western world.
onclusions
This study shows that differences in clinical outcomes after
PCI with DES in DM patients do exist, although to a lesser
extent when compared with non-DM patients, and that
treatment with EES is associated with improved clinical
outcomes, as compared with first-generation PES and SES,
in all-comer DM patients. This finding reflects mainly the
lower rates of ST and mortality with EES, which in turn
might reflect the improvements in stent design of this
second-generation device. These findings should prompt
further dedicated and properly powered clinical trials to
assess the performance of newer-design rapamycin-analogs
or PES in DM patients.
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